Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat

• Published in: Physiological reports Vol. 8; no. 10; pp. e14448 - n/a
• Main Authors: Leader, Catherine J., Kelly, Darren J., Sammut, Ivan A., Wilkins, Gerard T., Walker, Robert J.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.05.2020; John Wiley and Sons Inc; Wiley
• Subjects: Aldosterone - metabolism; Animals; Blood pressure; Blood Pressure - drug effects; Cardiovascular disease; Connective tissue growth factor; Creatinine; Diet; Disease Models, Animal; Feeds; Fibrosis; Fibrosis - etiology; Fibrosis - genetics; Fibrosis - pathology; Fibrosis - prevention & control; Hypertension; Hypertension - genetics; Indoles; Infiltration; Inflammation; kidney; Kidney diseases; Kidney Diseases - etiology; Kidney Diseases - pathology; Kidney Diseases - prevention & control; Macrophages; Male; Mineralocorticoid Receptor Antagonists - pharmacology; Original Research; Physiology; Proteins; Proteinuria; Rats; Rats, Transgenic; Renal cortex; spironolactone; Spironolactone - pharmacology; Urine; New Zealand; kidney; fibrosis; hypertension; spironolactone
• ISSN: 2051-817X; 2051-817X
• DOI: 10.14814/phy2.14448

Hypertension plays an important role in the development and progression of chronic kidney disease. Studies to date, with mineralocorticoid receptor antagonists (MRA), have demonstrated varying degrees of results in modifying the development of renal fibrosis. This study aimed to investigate whether treatment with a MRA commenced following the establishment of hypertension, a situation more accurately representing the clinical setting, modified the progression of renal fibrosis. Using male Cyp1a1Ren2 rats (n = 28), hypertension was established by addition of 0.167% indole‐3‐carbinol (w/w) to the rat chow, for 2 weeks prior to treatment. Rats were then divided into normotensive, hypertensive (H), or hypertensive with daily oral spironolactone treatment (H + SP) (human equivalent dose 50 mg/day). Physiological data and tissue were collected after 4 and 12 weeks for analysis. After 4 weeks, spironolactone had no demonstrable effect on systolic blood pressure (SBP), proteinuria, or macrophage infiltration in the renal cortex. However, glomerulosclerosis and renal cortical fibrosis were significantly decreased. Following 12 weeks of spironolactone treatment, SBP was lowered (not back to normotensive levels), proteinuria was reduced, and the progression of glomerulosclerosis and renal cortical fibrosis was significantly blunted. This was associated with a significant reduction in macrophage and myofibroblast infiltration, as well as CTGF and pSMAD2 expression. In summary, in a model of established hypertension, spironolactone significantly blunted the progression of renal fibrosis and glomerulosclerosis, and downregulated the renal inflammatory response, which was associated with reduced proteinuria, despite only a partial reduction in systolic blood pressure. This suggests a blood pressure independent effect of MRA on renal fibrosis. In the setting of severe hypertension, spironolactone reduces kidney fibrosis independent of a hypotensive effect. Mineralocorticoid receptor antagonism reduces hypertensive‐mediated kidney fibrosis.